Virological tools for hepatitis C - re-treatment and resistance

Joop Arends and Will Irving
Agenda for this morning

• Warming-up questions to the audience

• Review of (inter)national guidelines on retreatment

• Review of clinical trial-data

• Data on NHS England Expanded Access programme (decompensated cirrhotics)

• Review of virological methodologies for identifying resistance

• Case histories for discussion
Questions for the audience

• Are DAAs unrestricted reimbursed in your country?

• Are DAAs reimbursed for DAA treatment failures?

• Do you perform baseline resistance testing before starting DAA therapy?

• Do you perform resistance testing after DAA treatment failure?
Review of international guidelines

This topic will discuss the most recent EASL and AASLD guidelines on baseline resistance testing and resistance testing upon DAA treatment failure.
Review of clinical trial-data

In this section, (un)disclosed clinical data will be discussed.
NHS England Expanded Access programme

- Allowed all-oral DAA therapy for patients with life-threatening liver disease (decompensated cirrhosis)
- Around 110 virological treatment failures
- Data on SVR rates on re-treatment, and association with pre-re-treatment resistance variants will be presented
Virological methodologies for identifying resistance

• The differences between Sanger sequencing and next generation sequencing will be outlined.
• Data indicating that at least in some circumstances, resistance testing does have meaningful clinical impact will be shown.
Case histories

In this section, clinical cases will be discussed